CCR2 and glioblastoma: To this end, we compared the GBM take rate in mice depleted of Treg cells (FoxP3DTR mice, treated with DT prior to tumor inoculation) vs. Ccr2–/– mice that are unable to recruit monocytic TAM precursors to tumor sites (Supplementary Fig. 10b).